Skip to main content
. 2010 Jul 1;118(8):2069–2076. doi: 10.1182/blood-2011-01-330563

Table 2.

Nonhematological toxicities in patients included in phase 2

Adverse event All grade (%) Grade > 3, %
Diarrhea 6.7 0
Fatigue 16.9 0
Musculoskeletal 33.3 0
Stomatitis 70 3
Skin disorders 36.7 0
Bleeding 13.3 0
Hypertriglyceridemia 70 0
Hypercholesterolemia 23.3 0
AST increase 7 3
ALT increase 7 3
Bronchitis 3 0
Pneumonitis 7 7
Urinary tract infection 7 3
Renal failure 3 3
Others 20 0

ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.